Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Rolski, J. [1 ]
Grodzki, T. [2 ]
Schneider, C. P. [3 ]
Zatloukal, P. [4 ]
Reck, M. [5 ]
Aitin, E. [6 ]
Tan, E. H.
机构：
[1] Maria Sklodowska Curie Mem Inst Oncol, Krakow, Poland
[2] Reg Hosp Lung Dis, Szczecin, Poland
[3] Cent Clin Bad Berka, Bad Berka, Germany
[4] Pneumol Clin, Prague, Czech Republic
[5] Krankenhaus Grosshansdorf, Grosshansdorf, Germany
[6] Hosp Carlo Poma, Mantova, Italy
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71329-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6501
引用
收藏
页码：356 / 356
页数：1
相关论文
共 50 条
  • [21] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [22] Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
    Kelly, K
    Crowley, J
    Bunn, PA
    Presant, CA
    Grevstad, PK
    Mainpour, CM
    Ramsey, SD
    Wozniak, AJ
    Weiss, GR
    Moore, DF
    Israel, VK
    Livingston, RB
    Gandara, DR
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3210 - 3218
  • [23] Navelbine (NVB) oral (o) with cisplatin (CDDP) as induction and concomitant to radiotherapy (RT): Final results of an international phase II trial in stage III non-small cell lung cancer (NSCLC)
    Utracka-Hutka, B.
    Krzakowski, M.
    Provencio, M.
    Villa, E.
    Codes, M.
    Kuten, A.
    Riggi, M.
    Caux, N.
    Longerey, B.
    Dubray, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial
    Binder, Daniel
    Beinert, Thomas
    Schweisfurth, Hans
    Grah, Christian
    Temmestfeld-Wollbrueck, Bettina
    Schaeper, Christoph
    Mueller-Hagen, Gerit
    Schuermann, Dirk
    Suttorp, Norbert
    ANNALS OF ONCOLOGY, 2004, 15 : 178 - 178
  • [25] A randomized phase III trial of tirapazamine (T) in combination with cisplatin (C) and vinorelbine (V) versus cisplatin and vinorelbine in advanced non-small cell lung cancer (NSCLC)
    LeChevalier, T.
    Gatzemeier, U.
    Breton, J. L.
    Cigolari, S.
    Stewart, D.
    Von Pawel, J.
    Firvida, J. L.
    Barcelo, J. R.
    Shen, L.
    Loh, E. Y.
    ANNALS OF ONCOLOGY, 2004, 15 : 165 - 165
  • [26] A prospective evaluation of quality of life (QOL) in a phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Raju, R. N.
    Socinski, M.
    Stinchcombe, T.
    Couch, L. S.
    Kocs, D. M.
    Jotte, R.
    Wang, Y.
    Bromund, J.
    Marciniak, M.
    Obasaju, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] A phase II trial of high-dose gemcitabine (GEM) plus cisplatin (CDDP) in advanced non small cell lung cancer(NSCLC).: Preliminary results.
    Isla, D
    Mayordom, JI
    Yubero, A
    Cajal, R
    Bueso, P
    Herráez, J
    Martí, JL
    Murillo, L
    Sáenz, A
    Escudero, P
    García-Prats, MD
    Tres, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S67 - S67
  • [28] Activity, safety and compliance of sequential chemotherapy with cisplatin (CDDP) plus oral vinorelbine (VNRos) followed by three-weekly docetaxel (DOC) as first-line treatment for advanced non-small cell lung cancer (NSCLC): a single-centre phase II study
    Teragni, C.
    Palumbo, R.
    Bernardo, A.
    Strada, M. R.
    Poggi, G.
    Amatu, A.
    Montagna, B.
    Tagliaferri, B.
    Sottotetti, F.
    Bernardo, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 532 - 532
  • [29] A phase I trial of weekly docetaxel (DTX) and cisplatin (CDDP) concomitant with thoracic radiation therapy (TRT) for patients with unresectable locally advanced non-small-cell lung cancer (NSCLC).
    Moriyama, A
    Komiya, K
    Yamamoto, N
    Nakagawa, K
    Fukuoka, M
    ANNALS OF ONCOLOGY, 2000, 11 : 110 - 110
  • [30] Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX).
    Von Pawel, J.
    Park, K.
    Pereira, J. R.
    Szczesna, A.
    Yu, C.
    Ganul, V. L.
    Krzakowski, M.
    Roh, J. K.
    Pilz, K.
    Pirker, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 391S - 391S
12345